Parametersa | Values | Range | Distribution | Sources |
---|---|---|---|---|
General Mortality | 0.0119 | ±25% | Log Normal | China Health and Family Planning Statistical Yearbook 2013 [18] |
Relative risk of CKD Mortality | 1.63 | 1.5–1.77 | Log Normal | Chronic Kidney Disease Prognosis Consortium 2010 [30] |
Relative risk reduction of CKD mortality after treatment | 0.24 | 0.08–0.37 | Log Normal | Heart Outcomes Prevention Evaluation (HOPE) Study Investigators 2000 [22] |
Cost | ||||
DAY-1 | 24.0 | ±25% | Gamma | Market price [21] |
Random | 24.0 | |||
DAY-1+ Random | 48.0 | |||
DAY-1+ Random + DAY-2 | 72.0 | |||
RAS inhibitors | 2867.2 | |||
CKD annual cost | 34205.0 | Gamma | Wu et al.2014 [20] | |
Quality-Adjusted of Life Years | ||||
CKD | 0.899 | ±0.145 | Beta | Wu et al.2014 [20] |